Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

March 27, 2019

Study Completion Date

July 27, 2019

Conditions
Venous ThromboembolismDeep Venous ThrombosisSurgery
Interventions
DRUG

Fixed Dose Enoxaparin

Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.

DRUG

Variable Dose Enoxaparin

Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.

Trial Locations (1)

84112

University of Utah, Salt Lake City

All Listed Sponsors
collaborator

University of Michigan

OTHER

lead

University of Utah

OTHER

NCT03251963 - Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients | Biotech Hunter | Biotech Hunter